MetaCap

Precision BioSciences Inc. (DTIL)

NASDAQ: DTILHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

7.40+0.49 (+7.09%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

DTIL stock chart

Technical analysis

Key statistics

All statistics
Market cap
$282.46M
52-week range
3.53 – 11.29
Day range
6.77 – 7.55
Volume / Avg
429.79K / 319.79K
Beta
—

52-week range

$3.53$11.29

DTIL stock today

Shares of Precision BioSciences (DTIL) finished higher on Nov 20 at $7.40, a gain of 7.09% or $0.49 per share, versus the S&P 500's 3.70% decline. Shares are 34.5% below their 52-week high of $11.29, set on Nov 5, 2026 and 109.6% above the 52-week low of $3.53, in the middle of the past year's range. DTIL is up 77.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 48.0%.

Precision BioSciences trades at 29.6x its trailing twelve-month earnings per share of $0.25.

Summary generated from market data by MetaCap's automated system. Methodology

About Precision BioSciences

Company profile

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Michael Amoroso
Headquarters
Durham, NC
Employees
69
IPO year
2019

Financial highlights

Full financials

In fiscal 2025, Precision BioSciences generated $34.3 million in revenue, down 50.1% from fiscal 2024, its first annual decline since 2022. Precision BioSciences reported a net loss of $45.7 million, compared with net income of $7.2 million a year earlier. Operating margin was -152.2%.

Precision BioSciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$34.26M$68.70M$48.73M$25.10M$115.53M
Growth-50.12%+40.98%+94.15%-78.28%+375.72%
Net income$-45.72M$7.17M$-61.32M$-111.64M$-30.60M
EPS (diluted)$-3.56$1.04$-15.96$-38.10$-0.52

Analyst forecast

Forecast

Consensus (5 analysts)

strong_buy

Avg. price target

$29.40+297.30%

  • Strong buy 0
  • Buy 5
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $18.00High $60.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 3, 2026
EPS actual vs est.
$-1.84 vs $-1.02
Surprise
-80.39%

DTIL news

All DTIL news

Precision BioSciences peers

Health Care sector
DTIL peer companies
CompanyPrice% ChgMarket capCompare
AGENAgenus Inc.5.97-2.77%$270.12Mvs DTIL
KYTXKyverna Therapeutics Inc.4.26-2.52%$269.33Mvs DTIL
AGMBAgomAb Therapeutics NV ADR5.45-3.02%$268.40Mvs DTIL
TRXBTRex Bio Inc.10.32+6.12%$296.95Mvs DTIL
OCGNOcugen Inc.0.7679+4.79%$260.55Mvs DTIL
XFORX4 Pharmaceuticals Inc.3.00+1.35%$306.34Mvs DTIL
EIKNEikon Therapeutics Inc.4.74-0.42%$256.84Mvs DTIL
SLBTSL Science Holding Limited0.55-3.36%$308.42Mvs DTIL

Indexes, lists and sector

Precision BioSciences stock FAQ

What is Precision BioSciences's stock price today?

DTIL last traded at $7.40 as of Nov 20, 4:00 PM EST, up 7.09% on the day. Prices are delayed at least 15 minutes.

Does Precision BioSciences pay a dividend?

No. Precision BioSciences does not currently pay a regular cash dividend.

What is DTIL's P/E ratio?

DTIL trades at a trailing P/E ratio of 29.60.

Who is Precision BioSciences's CEO?

Mr. Michael Amoroso is the chief executive officer of Precision BioSciences Inc., which has about 69 employees.

Has DTIL ever split its stock?

Yes. The most recent DTIL stock split was a 1-for-30 split on Feb 14, 2024.

What is the DTIL 52-week high?

The 52-week high for DTIL is $11.29 and the 52-week low is $3.53. The stock is currently 34.5% below its high.

Compare DTIL